References
- Armitage J. O., Fyfe A. E., Lewis J. Long-term remission durability and functional status of patients treated for diffusse histiocytic lymphoma with the CHOP regimen. J Clin Oncol 1985; 3: 1187–1195
- Shipp M. A., Yeap B. Y., Hanington D., et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: Analysis of the completed trial and comparation with the M-BACOD regimen. J. Clin Oncol 1990; 8: 84–93
- Fisher R. I., Gaynor E. R., Dahlberg S., et al. Comparison of standard regimen (CHOP) with intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328(14)1002–1006
- Homing S. J., Rosenberg S. A. The natural history of initially untreated low grade non-Hodgkin's lym-phomas. N Engl J Med 1984; 311: 1471–1475
- Velazquez W. S., McLaughlin P., Tucker S., et al. ESHAP-An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 1994; 12: 1169–1176
- Velazquez W. S., Cabanillas F., Salvador P., et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexarnethassone (DHAP). Blood 1988; 71: 117–122
- Cabanillas F., Hagemeister F., McLaughlin P., et al. Results of MIME salvage therapy for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407–412
- Cabanillas F. Experience with salvage regimens at MD Anderson Hospital. Ann Oncol 1991; 2(suppl 1)31–32
- Casazza A. M., Pratesi G., Giuliana F., Dimarco A. Anti-leukaemic activity of 4– demethoxydaunorubicin in mice. Tumori 1980; 66: 549
- Case D. C., Gerber M. C., Gams R. A. Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma. Leukemia & Lymphoma 1993; 10: 73–79
- Coonley C. J., Warrell R. P., Strauss D. J., Young C. W. Clinical evaluation of 4-demethoxydaunorubicin in patients with advanced malignant lymphoma. Cancer Treat Rep 1983; 67: 949–950
- Lopez M., Dilauro L., Papaldo P. Oral idarubicin in non-Hodgkin's lymphoma. Invest New Drugs 1986; 4: 263–267
- Case D. C., Hayes D. M., Gerber M. Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma. Cancer Rex 1990; 50: 6833–35
- Gillies H., Liang R., Roger S. H., et al. Phase II trial of idarubicin in patients with advanced lymphoma. Cancer Chemother Pharmacol. 1988; 21: 261–264
- Wilson W. H., Bryan G., Bates S., et al. EPOCH Chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573–1582
- Rodriguez M. A., Cabanillas F., Hagemeister F., et al. MINE-ESHAP: a novel and effective salvage combination for lymphoma. Proc Am Soc Clin Oncol (. San Diego 1992; 1992, 11, 327, 1114 (abstr).
- Dupont J., Garay G., Cacchione R., et al. Treatment of refractory and relapsed lymphoma. MIZE protocol (MESNA-Ifosfamide, idarubicin and etoposide). Proc Am Soc Clin Oncol (. Dallas 1994; 1994, 13, 380, 1291 (abstr).
- Schnell R., KÜPper F., Reiser M., Engelhard M., et al. A clinical phase II trial with Idarubicin, Ifosfamide and VP-16 (IIVP-16) in patients with relapsed high-grade non-Hodgkin's lymphoma. Annals of Oncology 1996; 3(Suppl 3)158, 587 (abstr)
- Philip T., Guglielmi C., Chauvin F., et al. Autologous bone marrow transplantation vs. conventional Chemotherapy (DHAP) in relapsed non Hodgkin Lymphoma: Final analysis of the Parma randomized study (216 patients). Proc Am Soc Clin Oncol (. Los Angeles 1995; 1995, 14, 390, 1220 (abstr).